Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
CSE: ALEN.U — AI Meets Digital Health (click to learn more) What’s Behind Cannabis Stock HERB? (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.


NDAQ:GRCE - Post by User

Grace Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(80)
•••
  • bingostarX
Post by bingostaron Dec 22, 2022 6:08pm
590 Views
Post# 35188229

the perfect situation

the perfect situationWith a market cap  trading  under the cash in the cie and 3 products in clinic phase announcing news in the coming weeks you cannot dream of a better scenario . On top of it the CEO Pierre Lemieux who sold Biolactis to Nestl for a massive gain could deal an historic deal with a big pharma for 1 or all products in the pipeline. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities